Adding hydroxyurea to standard salvage therapy for relapsed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial adds a drug called hydroxyurea to a standard combination of chemotherapy for AML that has not responded to treatment or has come back. The hope is that adding hydroxyurea may make the other drugs work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that either did not go into remission after initial treatment, or has come back after a remission (including minimal residual disease).
- You are 18 to 74 years old.
- You are well enough to receive intensive chemotherapy, and your daily activities are not severely limited (ECOG 0-2).
- Your kidney and liver function are within acceptable ranges.
- You are not pregnant, and you follow birth control rules if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral drugs (hydroxyurea and valproic acid, or 6-mercaptopurine and valproic acid) for people with AML or high-risk MDS who are too frail for standard chemotherapy. The goal is to see if this gentler treatment can help control the disease.
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This trial tests a combination of three drugs (hydroxychloroquine, decitabine, and venetoclax) for people with acute myeloid leukemia (AML) that is either hard to treat or very high-risk. The goal is to see if this combination can help control the leukemia and what side effects it may cause.
This trial tests a combination of three drugs (sonrotoclax, cladribine, and cytarabine) as a rescue treatment for people whose acute myeloid leukemia (AML) has come back or not responded to previous treatment. The goal is to prepare patients for a stem cell transplant, which may offer a chance for long-term remission.
This trial tests a combination of three drugs (VAH) as a 'bridge' to prepare patients with acute myeloid leukemia (AML) that has come back or not responded to standard treatment for a stem cell transplant. The goal is to see if VAH can help achieve remission and improve transplant outcomes.
Hear when a new R/R AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.